Lotus Pharmaceutical Co Ltd (1795)
Taiwan Stock Exchange · Taiwan · prices in TWD · close of 20 Oct 2026
Key indicators
| Last close | TWD 175.00 |
|---|---|
| 52-week range | 170.50 – 369.50 |
| Return, 1 month / 3 months | −1.7% / −7.4% |
| Return, 1 year / 3 years | −34.2% / −28.9% |
| Trend | Below its 200-day average |
| RSI (14) | 42 |
| Volatility (1 year) | 44.0% |
| Worst drawdown (1 year) | -52.3% |
| Average daily value traded | 184.84M TWD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Lotus Pharmaceutical is a specialty pharmaceutical company based in Taiwan. It develops, makes and markets generic and branded medicines, with a focus on oncology and other hospital-based treatments, and it also produces active ingredients and finished dosage forms. Its customers are hospitals, clinics and distributors, and it serves patients in Taiwan and through partners and subsidiaries in other markets. The company handles the development, manufacturing and commercialisation of its products in house.
The shares are listed on the Taiwan Stock Exchange in Taiwan under the code 1795, and the price on this page is in New Taiwan dollars (TWD). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Lotus Pharmaceutical Co Ltd (1795) trades on the Taiwan Stock Exchange in Taiwan. It last closed at TWD 175.00 on 20 October 2026.
Its price-based Market X-Ray is 23 out of 100 (a weak price profile), ranking 1,013 of 1,101 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 34.2% and over the last three months it fell 7.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Taiwan Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 4 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -21.5% | ||
| From 52-week high | -51.8% | ||
| Momentum | 13 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -7.4% | ||
| 6-month return | -22.6% | ||
| 12-month return, skipping the last month | -33.1% | ||
| Stability (higher is calmer) | 23 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 44.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -52.3% | ||
| Liquidity | 74 · Strong | Trades actively. | |
| Average daily value traded | 184.84M TWD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −1.7% |
|---|---|
| 1 month | −1.7% |
| 3 months | −7.4% |
| 6 months | −22.6% |
| 1 year | −34.2% |
| 3 years | −28.9% |
| 5 years | – |
Signals
| 50-day / 200-day average | 182.15 / 222.82 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.10 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 Jul 2023 | TWD 3.4599 |
| 4 Aug 2022 | TWD 1.9312 |
| 7 Jul 2021 | TWD 0.3500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Taiwan Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.